The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“…are approximately 15% (Hodi et al., 2010; Robert et al., 2011); those following targeting of the PD-1-PD-L1 axis rarely exceed 40% (and are often considerably beneath this figure), and there are a large number of partial responders (Brahmer et al., 2012; Hamid et al., 2013; Topalian et al., 2012).”
InfluentialA core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823
Human gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Linking long-term dietary patterns with gut microbial enterotypes
Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.-Y., Keilbaugh, S. A., Bewtra, M., Knights, D., Walters, W. A., Knight, R., et al. (2011) · Science · doi:10.1126/science.1208344 · Cited by 6,513
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Richness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 7×
“1262 Immunity 44, June 21, 2016 the gut microbiota, especially Bifidobacterium, in promoting natural anti-tumor immune responses (Sivan et al., 2015).”
InfluentialInduction of Colonic Regulatory T Cells by Indigenous Clostridium Species
Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T., Ohba, Y., et al. (2011) · Science · doi:10.1126/science.1198469 · Cited by 3,752
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 13×
“fragilis to promote the proliferation of ICOS Treg cells in the lamina propria, possibly through mobilizing plasmacytoid DCs (this cell type has been observed to accumulate and mature in mesenteric lymph nodes after B. fragilis monocolonization of germ-free mice treated with anti-CTLA-4 mAb; Dasgupta et al., 2014; Vét…”
InfluentialSelf-citationSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Self-citationThe Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice
Turnbaugh, P. J., Ridaura, V. K., Faith, J. J., Rey, F. E., Knight, R., & Gordon, J. I. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000322 · Cited by 3,058 · cited 2×
“…generally stable within each individual (Gophna, 2011), there exists a vast level of inter-individual heterogeneity (even between identical twins; Turnbaugh et al., 2009a) that is largely determined by the diet (Turnbaugh et al., 2009b; Wu et al., 2011) and environment (Lin et al., 2013;…”
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Self-citationTreg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
The gut microbiota, bacterial metabolites and colorectal cancer
Louis, P., Hold, G. L., & Flint, H. J. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3344 · Cited by 2,816
Coombes, J. L., Siddiqui, K. R. R., Arancibia-Cárcamo, C. V., Hall, J., Sun, C.-M., Belkaid, Y., & Powrie, F. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070590 · Cited by 2,710
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
A microbial symbiosis factor prevents intestinal inflammatory disease
Mazmanian, S. K., Round, J. L., & Kasper, D. L. (2008) · Nature · doi:10.1038/nature07008 · Cited by 2,340
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Role of the gut microbiota in immunity and inflammatory disease
Kamada, N., Seo, S.-U., Chen, G. Y., & Núñez, G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3430 · Cited by 2,256
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
An integrated catalog of reference genes in the human gut microbiome
MetaHIT Consortium, Li, J., Jia, H., Cai, X., Zhong, H., Feng, Q., Sunagawa, S., Arumugam, M., Kultima, J. R., Prifti, E., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2942 · Cited by 2,164
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Self-citationTLR4 mutations are associated with endotoxin hyporesponsiveness in humans
Arbour, N. C., Lorenz, E., Schutte, B. C., Zabner, J., Kline, J. N., Jones, M., Frees, K., Watt, J. L., & Schwartz, D. A. (2000) · Nature Genetics · doi:10.1038/76048 · Cited by 2,024
Reciprocal T H 17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid
Mucida, D., Park, Y., Kim, G., Turovskaya, O., Scott, I., Kronenberg, M., & Cheroutre, H. (2007) · Science · doi:10.1126/science.1145697 · Cited by 1,982
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Sun, C.-M., Hall, J. A., Blank, R. B., Bouladoux, N., Oukka, M., Mora, J. R., & Belkaid, Y. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070602 · Cited by 1,881
Dietary intervention impact on gut microbial gene richness
Cotillard, A., Kennedy, S. P., Kong, L. C., Prifti, E., Pons, N., Le Chatelier, E., Almeida, M., Quinquis, B., Levenez, F., Galleron, N., et al. (2013) · Nature · doi:10.1038/nature12480 · Cited by 1,832
Self-citationSpranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota
Round, J. L., Lee, S. M., Li, J., Tran, G., Jabri, B., Chatila, T. A., & Mazmanian, S. K. (2011) · Science · doi:10.1126/science.1206095 · Cited by 1,604
Gut-Residing Segmented Filamentous Bacteria Drive Autoimmune Arthritis via T Helper 17 Cells
Wu, H.-J., Ivanov, I. I., Darce, J., Hattori, K., Shima, T., Umesaki, Y., Littman, D. R., Benoist, C., & Mathis, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.06.001 · Cited by 1,577
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Garrett, W. S. (2015) · Science · doi:10.1126/science.aaa4972 · Cited by 1,404
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis
Lee, Y. K., Menezes, J. S., Umesaki, Y., & Mazmanian, S. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000082107 · Cited by 1,323
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,231
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
MetaHIT Consortium, Nielsen, H. B., Almeida, M., Juncker, A. S., Rasmussen, S., Li, J., Sunagawa, S., Plichta, D. R., Gautier, L., Pedersen, A. G., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2939 · Cited by 1,184
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Self-citationCyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.015 · Cited by 1,128
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Self-citationCancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
Self-citationPotentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
Yang, W., Bai, Y., Xiong, Y., Zhang, J., Chen, S., Zheng, X., Meng, X., Li, L., Wang, J., Xu, C., et al. (2016) · Nature · doi:10.1038/nature17412 · Cited by 1,010
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
Self-citationThe Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 864
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
Lagier, J.-C., Hugon, P., Khelaifia, S., Fournier, P.-E., La Scola, B., & Raoult, D. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-14 · Cited by 831
Understanding immunosenescence to improve responses to vaccines
Goronzy, J. J., & Weyand, C. M. (2013) · Nature Immunology · doi:10.1038/ni.2588 · Cited by 827 · cited 1×
“For example, segmented filamentous bacteria (SFB) are potent inducers of Th17 and Th1 cells in the small intestine (Goto et al., 2014; Ivanov et al., 2009).”
Gao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Immunogenicity of somatic mutations in human gastrointestinal cancers
Tran, E., Ahmadzadeh, M., Lu, Y.-C., Gros, A., Turcotte, S., Robbins, P. F., Gartner, J. J., Zheng, Z., Li, Y. F., Ray, S., et al. (2015) · Science · doi:10.1126/science.aad1253 · Cited by 729
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Platten, M., Wick, W., & Van den Eynde, B. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0569 · Cited by 703
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Spencer, M. D., Hamp, T. J., Reid, R. W., Fischer, L. M., Zeisel, S. H., & Fodor, A. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.049 · Cited by 593
Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1508-5 · Cited by 560
Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552
Microbial Dysbiosis Is Associated with Human Breast Cancer
Xuan, C., Shamonki, J. M., Chung, A., DiNome, M. L., Chung, M., Sieling, P. A., & Lee, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083744 · Cited by 543
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541 · cited 1×
“Hence, MDSCs have been reported to be potential predictors of resistance to the anti-CTLA-4 mAb ipilimumab in patients with prostate cancer or melanoma (Martens et al., 2016; Meyer et al., 2014; Santegoets et al., 2014).”
Microbiome and Anticancer Immunosurveillance
Zitvogel, L., Ayyoub, M., Routy, B., & Kroemer, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.001 · Cited by 478
Self-citationSchadendorf, D., Ugurel, S., Schuler-Thurner, B., Nestle, F. O., Enk, A., Bröcker, E.-B., Grabbe, S., Rittgen, W., Edler, L., Sucker, A., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj138 · Cited by 467
Goto, Y., Panea, C., Nakato, G., Cebula, A., Lee, C., Diez, M. G., Laufer, T. M., Ignatowicz, L., & Ivanov, I. I. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.005 · Cited by 465
Cancer and the gut microbiota: An unexpected link
Zitvogel, L., Galluzzi, L., Viaud, S., Vétizou, M., Daillère, R., Merad, M., & Kroemer, G. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010473 · Cited by 465
Self-citationChemotherapy-induced antitumor immunity requires formyl peptide receptor 1
Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., et al. (2015) · Science · doi:10.1126/science.aad0779 · Cited by 452
Self-citationTouchefeu, Y., Montassier, E., Nieman, K., Gastinne, T., Potel, G., Bruley des Varannes, S., Le Vacon, F., & de La Cochetière, M. F. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12878 · Cited by 425
Smoking Cessation Induces Profound Changes in the Composition of the Intestinal Microbiota in Humans
Biedermann, L., Zeitz, J., Mwinyi, J., Sutter-Minder, E., Rehman, A., Ott, S. J., Steurer-Stey, C., Frei, A., Frei, P., Scharl, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059260 · Cited by 404
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 386
Antibiotics, microbiota, and immune defense
Ubeda, C., & Pamer, E. G. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.05.003 · Cited by 356
Barreira da Silva, R., Laird, M. E., Yatim, N., Fiette, L., Ingersoll, M. A., & Albert, M. L. (2015) · Nature Immunology · doi:10.1038/ni.3201 · Cited by 337
Antibiotic Use in Relation to the Risk of Breast Cancer
Velicer, C. M. (2004) · JAMA · doi:10.1001/jama.291.7.827 · Cited by 331
Xiao, Y., Yu, S., Zhu, B., Bedoret, D., Bu, X., Francisco, L. M., Hua, P., Duke-Cohan, J. S., Umetsu, D. T., Sharpe, A. H., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130790 · Cited by 321
Lin, A., Bik, E. M., Costello, E. K., Dethlefsen, L., Haque, R., Relman, D. A., & Singh, U. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053838 · Cited by 314
Rutkowski, M. R., Stephen, T. L., Svoronos, N., Allegrezza, M. J., Tesone, A. J., Perales-Puchalt, A., Brencicova, E., Escovar-Fadul, X., Nguyen, J. M., Cadungog, M. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.009 · Cited by 311
Natural and therapy-induced immunosurveillance in breast cancer
Kroemer, G., Senovilla, L., Galluzzi, L., André, F., & Zitvogel, L. (2015) · Nature Medicine · doi:10.1038/nm.3944 · Cited by 310
Self-citationDepleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 307
Nishijima, T. F., Muss, H. B., Shachar, S. S., & Moschos, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.006 · Cited by 293
Dasgupta, S., Erturk-Hasdemir, D., Ochoa-Reparaz, J., Reinecker, H.-C., & Kasper, D. L. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.03.006 · Cited by 292
Hakim, F. T., Flomerfelt, F. A., Boyiadzis, M., & Gress, R. E. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.01.009 · Cited by 272
Nagarsheth, N., Peng, D., Kryczek, I., Wu, K., Li, W., Zhao, E., Zhao, L., Wei, S., Frankel, T., Vatan, L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1938 · Cited by 271
Berman, D., Parker, S. M., Siegel, J., Chasalow, S. D., Weber, J. S., Galbraith, S. M., Targan, S. R., & Wang, H. L. (2010) · PubMed · Cited by 258
Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 256
Energy Balance, Host-Related Factors, and Cancer Progression
Hursting, S. D., & Berger, N. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.27.9935 · Cited by 252
A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
Ngiow, S. F., Young, A., Jacquelot, N., Yamazaki, T., Enot, D., Zitvogel, L., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1082 · Cited by 237 · cited 2×
“Comparison of anti-PD1-sensitive and anti-PD1-resistant tumors, which paradoxically both contain CD8+ T cells, has suggested that intratumoral Treg cells might be responsible for limiting antiPD1 mAb efficacy in cases where intratumoral T cell numbers appear sufficient (Ngiow et al., 2015).”
Self-citationA new vision of immunity: homeostasis of the superorganism
Eberl, G. (2010) · Mucosal Immunology · doi:10.1038/mi.2010.20 · Cited by 224
Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut
Morton, A. M., Sefik, E., Upadhyay, R., Weissleder, R., Benoist, C., & Mathis, D. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405634111 · Cited by 199
Fucikova, J., Becht, E., Iribarren, K., Goc, J., Remark, R., Damotte, D., Alifano, M., Devi, P., Biton, J., Germain, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1142 · Cited by 199
Self-citationCorrales, L., & Gajewski, T. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1362 · Cited by 197
The microbial basis of inflammatory bowel diseases
Dalal, S. R., & Chang, E. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72330 · Cited by 194
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV
Casrouge, A., Decalf, J., Ahloulay, M., Lababidi, C., Mansour, H., Vallet-Pichard, A., Mallet, V., Mottez, E., Mapes, J., Fontanet, A., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci40594 · Cited by 189
Microbiota regulates type 1 diabetes through Toll-like receptors
Burrows, M. P., Volchkov, P., Kobayashi, K. S., & Chervonsky, A. V. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508740112 · Cited by 174
Pawelec, G., Derhovanessian, E., & Larbi, A. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.06.012 · Cited by 173
Sandel, M. H., Dadabayev, A. R., Menon, A. G., Morreau, H., Melief, C. J. M., Offringa, R., van der Burg, S. H., Janssen-van Rhijn, C. M., Ensink, N. G., Tollenaar, R. A. E. M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1448 · Cited by 173
López-Albaitero, A., Lee, S. C., Morgan, S., Grandis, J. R., Gooding, W. E., Ferrone, S., & Ferris, R. L. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0697-4 · Cited by 160
Tarhini, A. A., Cherian, J., Moschos, S. J., Tawbi, H. A., Shuai, Y., Gooding, W. E., Sander, C., & Kirkwood, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.5394 · Cited by 160
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 136
Self-citationKabouridis, P. S., & Pachnis, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76308 · Cited by 126
Ladoire, S., Penault-Llorca, F. M., Senovilla, L., Dalban, C., Enot, D. P., Locher, C., Prada, N., Poirier-Colame, V., Chaba, K., Arnould, L., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1082022 · Cited by 116
Self-citationSantegoets, S. J. A. M., Stam, A. G. M., Lougheed, S. M., Gall, H. E., Jooss, K. U., Sacks, N., Hege, K. M., Lowy, I., Scheper, R. J., Gerritsen, W. R., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0031-3 · Cited by 112
Fcγ receptors: genetic variation, function, and disease
Hargreaves, C. E., Rose-Zerilli, M. J. J., Machado, L. R., Iriyama, C., Hollox, E. J., Cragg, M. S., & Strefford, J. C. (2015) · Immunological Reviews · doi:10.1111/imr.12341 · Cited by 105
Immunotherapy: The Path to Win the War on Cancer?
Topalian, S. L., Wolchok, J. D., Chan, T. A.-T., Mellman, I., Palucka, K., Banchereau, J., Rosenberg, S. A., & Wittrup, K. D. (2015) · Cell · doi:10.1016/j.cell.2015.03.045 · Cited by 99
Dutoit, V., Rubio‐Godoy, V., Pittet, M. J., Zippelius, A., Dietrich, P., Legal, F. A., Guillaume, P., Romero, P. J., Cerottini, J., Houghten, R. A., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020242 · Cited by 99
Ménétrier‐Caux, C., Curiel, T. J., Faget, J., Manuel, M., Caux, C., & Zou, W. (2012) · Targeted Oncology · doi:10.1007/s11523-012-0208-y · Cited by 93
(2002) · PubMed · Cited by 92
Going back to class I: MHC and immunotherapies for childhood cancer
Haworth, K. B., Leddon, J. L., Chen, C., Horwitz, E. M., Mackall, C. L., & Cripe, T. P. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25359 · Cited by 87
Wang, J., Chang, C., Lin, J., Wu, L., Chuang, L., & Lai, M. (2014) · International Journal of Cancer · doi:10.1002/ijc.28738 · Cited by 81
Association of HLA phenotype with response to active specific immunotherapy of melanoma.
Mitchell, M. S., Harel, W., & Groshen, S. G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1158 · Cited by 80
Auclair, J., Frappier, M., & Millette, M. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ179 · Cited by 70
Tarhini, A. A., Butterfield, L. H., Shuai, Y., Gooding, W. E., Kaliński, P., & Kirkwood, J. M. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318272569b · Cited by 62
Optimization of Immunotherapy in Elderly Cancer Patients
Tomihara, K., Curiel, T. J., & Zhang, B. (2013) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2013010591 · Cited by 59
Rubio‐Godoy, V., Dutoit, V., Zhao, Y., Simon, R. M., Guillaume, P., Houghten, R. A., Romero, P. J., Cerottini, J., Pinilla, C., & Valmori, D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5696 · Cited by 59
Riva, A., Laird, M. E., Casrouge, A., Ambrozaitis, A., Williams, R. L., Naoumov, N. V., Albert, M. L., & Chokshi, S. (2014) · Hepatology · doi:10.1002/hep.27139 · Cited by 53
Blomberg, B. B., Frasca, D., Diaz, A., & Antoni, M. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.210.supp.88.13 · Cited by 45
The potential for emerging therapeutic options forClostridium difficileinfection
Mathur, H., Rea, M. C., Cotter, P. D., Ross, R. P., & Hill, C. (2014) · Gut Microbes · doi:10.4161/19490976.2014.983768 · Cited by 39
Gophna, U. (2011) · Science · doi:10.1126/science.1213799 · Cited by 31
Ragab, D., Laird, M. E., Duffy, D., Casrouge, A., Mamdouh, R., Abass, A., ElShennawy, D. E.-S., Shebl, A. M., Elkashef, W. F., Zalata, K. R., et al. (2013) · Cytokine · doi:10.1016/j.cyto.2013.04.016 · Cited by 26
Chen, D.-N., Song, C.-G., Yu, K., Jiang, Y., Ye, F.-G., & Shao, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133184 · Cited by 20
Bioley, G., Guillaume, P., Luescher, I. F., Yeh, A., Dupont, B., Bhardwaj, N., Mears, G., Old, L. J., Valmori, D., & Ayyoub, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1747 · Cited by 19
A ‘fit’ microbiota to potentiate cancer immunotherapy
Rescigno, M. (2015) · Genome Medicine · doi:10.1186/s13073-015-0256-x · Cited by 12
Cited by
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Self-citationRegulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Metadata
- Authors
- Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., & Zitvogel, L.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 44
- Issue
- 6
- Pages
- 1255-1269
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2469758901
- Cited by
- 1,041
- References
- 169
- FWCI
- 40.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.